Efficacy of interventions in peripheral arterial and venous malformations of the limbs in children: protocol for a systematic review - Takeaways - MDSpire

Efficacy of interventions in peripheral arterial and venous malformations of the limbs in children: protocol for a systematic review

  • By

  • Zhaokun Guo

  • Zhongjing Zhang

  • Ying Jiang

  • Jun Zhou

  • Ke-Heng Deng

  • Wen-Xiang Zhu

  • Xiangyou Zhao

  • Pan Jiao

  • May 8, 2026

  • 0 min

Share

  • 1

    Peripheral arteriovenous malformations (pAVMs) in children are common and present unique clinical challenges due to their growth and developmental implications.

  • 2

    Current treatment options for pediatric extremity pAVMs include surgical resection, endovascular embolization, and sclerotherapy, each with distinct advantages and risks.

  • 3

    Research on the efficacy of treatments for pediatric pAVMs is limited, with most studies being small, uncontrolled, and lacking standardized evaluation criteria.

  • 4

    This systematic review will analyze existing studies to assess the efficacy and safety of various interventions for pediatric extremity pAVMs.

  • 5

    Findings from this review aim to provide evidence-based guidance for clinicians and improve treatment strategies for pediatric patients with pAVMs.

Original Source(s)

Efficacy of interventions in peripheral arterial and venous malformations of the limbs in children: protocol for a systematic review

  • by Zhaokun Guo, Zhongjing Zhang, Ying Jiang, Jun Zhou, Ke-Heng Deng, Wen-Xiang Zhu, Xiangyou Zhao, Pan Jiao

  • May 8, 2026

Related Content

Partly intraoperative cell salvage in pediatric craniocerebral trauma: effects on coagulation function, allogeneic blood requirements, and clinical outcomes — a propensity score-matched retrospective cohort study

Side Effects: Progress, with Asterisks

Burnout is easing. Sleep science is getting weird. And dental schools have been winging cadaver training for 50 years. This week's research is full of good news that immediately complicates itself.

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.